Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Apatinib plus pegylated liposo...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Apatinib plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer

Apatinib plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer

Bibliographic Details
Main Authors: Shushant Chib, Ajay Gogia
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Cancer Research, Statistics, and Treatment
Online Access:http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=793;epage=794;aulast=Chib
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=793;epage=794;aulast=Chib

Similar Items

  • Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
    by: I. A. Pokataev, et al.
    Published: (2015-11-01)
  • Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer
    by: Petronella O. Witteveen, et al.
    Published: (2010-11-01)
  • Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    by: Zhen Yuan, et al.
    Published: (2021-01-01)
  • Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
    by: María Jesús  Rubio Pérez
    Published: (2017-05-01)
  • Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
    by: Hiroyuki Yoshida, et al.
    Published: (2023-07-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs